Advancing understanding of maternal age: correlating epigenetic clocks in blood and myometrium

Elise N. Erickson1*, Anna K. Knight2, Alicia K. Smith2 and Leslie Myatt3

Abstract

Background: Advanced maternal age is currently a term defined by chronological age. However, a group of biomarkers known as epigenetic clocks, which can predict morbidity and mortality, has been used to estimate measures of biological aging. Uterine myometrial function during the process of parturition may be influenced by aging, as labor dystocia, unplanned intrapartum cesarean birth, and postpartum hemorrhage are more common in older individuals. The purpose of this study was to evaluate the use of epigenetic clocks in maternal myometrium and blood for predicting age and to evaluate the correlation of epigenetic age between the tissues.

Results: We compared epigenetic age in blood and myometrial samples provided by women undergoing planned cesarean birth at term gestation. Chronological age ranged from 20 to 50 with a median (IQR) age of 35.5(8) years. The MethylationEPIC BeadChip was used to obtain DNA methylation data, and then epigenetic age was calculated using the Horvath, Hannum, GrimAge, and PhenoAge clocks. Spearman correlations of epigenetic age with chronological age were calculated. We tested the relationship of epigenetic age in maternal blood to epigenetic age in myometrium. Age acceleration, for each clock, was also correlated between tissues. Twenty-seven participants provided samples, and 21 matched specimens were included in the final analysis after quality control. Spearman correlation between maternal chronological age and epigenetic age were significant in three of the four clocks (pan-tissue Horvath, Hannum, and GrimAge), for both myometrium and blood samples. Correlations between blood epigenetic age and maternal age ranged from 0.72 to 0.87 (all \( p < 0.001 \)). Correlations between myometrial epigenetic age and maternal age were also significant (0.62–0.70, \( p = 0.002 \)), though lower than correlations seen in blood. Maternal blood epigenetic age also correlated with epigenetic age in myometrium with each of these three clocks 0.60 (\( p = 0.004 \), Horvath), 0.63 (\( p = 0.003 \), Hannum), and 0.80 (\( p < 0.001 \), GrimAge). GrimAge age acceleration had the highest correlation between tissues among the clocks (0.49, \( p = 0.02 \)).

Conclusions: Given the limited sample, this study provides insight into the potential use of epigenetic age derived from blood as a proxy for myometrial epigenetic age, which may be a useful biomarker in estimating myometrial biological age in relationship to myometrial dysfunction. GrimAge outperformed the other tested clocks in terms of concordance of epigenetic age and age acceleration between tissues; however, the Horvath and Hannum clocks may be useful depending on the outcome of interest in pregnancy.

Keywords: Epigenome, Genetics, Maternal morbidity, Obstetrics, Parturition, Myometrium

Background

Advanced maternal age (AMA) is a designation based on an expectant mother having a chronological age of 35 or older. AMA status has been associated in population...
studies with childbirth-related morbidity [1–3]. While many factors influence the physiology of the birth process, the function of the uterine myometrium plays a critical role in labor onset, progress, and for third-stage labor/postpartum involution [4–7]. Labor dysfunction leading to unplanned cesarean and/or postpartum hemorrhage is more common in older individuals [1, 2, 8–10]. Some researchers have documented age-related changes in myometrial function; however, some discrepancies have been reported [11]. Associations include altered arterial impedance [12], myocyte cytoarchitecture [13], myometrial contractility [14], and response to oxytocin stimulation [15] in both human samples and animal models [16, 17]. However, dysfunctional labor, poor myometrial contractility, and hemorrhage also occur in younger populations and conversely many women aged 35 or older do not experience birth-related difficulties, suggesting that factors beyond maternal chronological age determine myometrial function [18].

Currently, determining the likelihood for adverse childbirth-related morbidity linked to myometrial function is not possible prior to labor from any available biomarker measurements or clinical metrics. Aside from prior history of labor dysfunction or a rare uterine anomaly (bicorunate uterus, etc.), clinicians have no tools to predict normal or abnormal parturition until labor begins. Developments in the understanding of biological aging, including epigenetic aging, have proved powerful predictors of morbidity and mortality in other adult populations and disease contexts, more so than chronological age or other previously used measures of biological age (i.e., telomere length). Epigenetic age is a molecular quantification of biological age, which may reflect underlying cellular senescence associated with aging or may be a consequence of the aging process itself [19, 20].

Epigenetic age is calculated based on DNA methylation, which is tissue-specific and changes reproducibly over time. Epigenetic clocks are used to estimate a biological measure of age based on a weighted average of groups of CpG sites and have been developed for a range of tissues and applications. Among the first clocks developed, the Horvath (Pan-Tissue) clock was validated on a large number of different tissue types, including some endometrial and cervical specimens, which may make it particularly relevant to myometrial function [21]. Next, the Hannum clock was created from a smaller set of CpG sites from whole blood in adults [22]. Both the Horvath and Hannum clocks were trained on chronological age, rather than being developed from survival data. The PhenoAge clock was validated against clinical parameters indicating physiologic dysregulation (albumin, creatinine, glucose, C-reactive protein, lymphocytes, mean red cell volume, red cell distribution width, alkaline phosphatase) which was not specific to pregnancy but may be relevant to aging parturient women who are also more likely to suffer metabolic and cardiovascular diseases both before and during pregnancy [23]. Finally, the GrimAge clock reflects a methylation pattern that is closely associated with smoking pack-years and levels of 7 plasma proteins that are associated with disease development/likelihood of death (adrenomedullin, beta-2-microglobulin, cystatin C, growth differentiation factor 15, Leptin, plasminogen activator inhibitor-1, and tissue inhibitor metalloproteinases-1) [24].

In addition to estimating biological age, the difference between biological age and chronological age can be informative as the speed at which these age-related changes occur varies from person to person. People experiencing more rapid aging have a biological age that is higher than their chronological age, which is termed age acceleration (AgeAccel). AgeAccel has previously been associated with all-cause mortality or the development of illness among several different clock methods [24, 25]. People with a lower biological age than their chronological age are experiencing age deceleration.

Variability in epigenetic age or AgeAccel has not been studied in myometrial tissue directly and may provide insight into biological aging and function/dysfunction in this key tissue during pregnancy. Few researchers have measured epigenetic age during pregnancy specifically, though a pilot study showed that epigenetic age (Horvath Pan-Tissue and GrimAge) of blood from 35 participants was older during mid-pregnancy when compared to 1 year postpartum [26]. Another similar study examined whole blood samples from 77 women in the second trimester, finding that maternal accelerated epigenetic age (using GrimAge) predicted a shorter gestational age at birth and lower birthweight in the newborn [27], implying AgeAccel may be useful for understanding pregnancy health or fetal growth.

As myometrium during pregnancy can only be accessed during surgical birth, the aim of this study was to determine if existing epigenetic clocks are associated with maternal age in both the myometrium and maternal blood (i.e., validity of the measures). Second, we sought to assess the association between epigenetic age and AgeAccel, measured in maternal blood and myometrium, to determine if blood epigenetic age and AgeAccel can serve as a proxy for myometrial epigenetic age and AgeAccel.

**Results**

The final study sample after quality control (n = 21) consisted of non-Hispanic, European/white (95%), multiparous individuals (77%) with a median (interquartile range, IQR) chronological age of 35.5 (8) years, mean
(SD) gestational age at delivery of 38.7 (0.8) weeks and mean (standard deviation, SD) pre-pregnancy body mass index of 27.8 (7.8) kg/m². Infant birth weight (grams) had a mean (SD) of 3192 (483). First, we calculated epigenetic age for each clock and compared it with chronological age. The median (IQR) blood epigenetic age for the pan-Tissue Horvath clock of 39.2 (8.8) years was significantly higher than chronological age ($p = 0.008$). Similarly, the median epigenetic age (Horvath) for myometrium was also higher at 49.4 (4.2) years ($p < 0.001$). Interestingly, median epigenetic age (Horvath) for myometrium was higher than chronological age ($p < 0.001$). Interestingly, Horvath’s pan-tissue clock estimated all myometrial specimens to be of age 40 or greater despite the chronological age at 49.4 (4.2) years ($p < 0.001$). Interestingly, Horvath’s pan-tissue clock estimated all myometrial specimens to be of age 40 or greater despite the chronological age of the sample spanning ages 20-50. The Hannum and GrimAge-derived epigenetic age estimates were significantly younger than chronological age for blood (Hannum $= 28.5$ (8.0) years, GrimAge $= 28.2$ (6.8) years, $p < 0.001$) and for myometrium (Hannum $= 19.7$ (5.0) years, GrimAge $= 32.7$ (6.9) years, $p = 0.002$).

We then examined the correlation between epigenetic age and chronological age for each tissue for the various clocks. Using a Spearman rho ($\rho$) of at least 0.5 as a benchmark (considered a moderate correlation [28]), we found that the Horvath, Hannum, and GrimAge clocks met criteria with significant correlations of epigenetic age with chronological age in both tissues (Table 1).

### Table 1

| Correlation                        | Epigenetic clock | $\rho$ | $p$ value |
|------------------------------------|------------------|--------|-----------|
| Blood epigenetic age with maternal age | Horvath          | 0.72   | <0.0001   |
|                                    | Hannum           | 0.87   | <0.0001   |
|                                    | PhenoAge         | 0.73   | <0.0001   |
|                                    | GrimAge          | 0.80   | <0.0001   |
| Myometrial epigenetic age with maternal age | Horvath          | 0.62   | 0.002     |
|                                    | Hannum           | 0.63   | 0.002     |
|                                    | PhenoAge         | 0.22   | 0.33      |
|                                    | GrimAge          | 0.70   | <0.0001   |

| Then, we calculated AgeAccel. The correlations between age acceleration between the two tissues shown in Table 2. Notably, GrimAge Accel between the two tissues had the highest correlation of the clocks we tested $\rho$ of 0.49 ($p = 0.02$).

We examined maternal pre-pregnancy body mass index (BMI) in relationship to blood epigenetic age derived from each clock as a post-hoc examination; however, no correlations were statistically significant. Myometrial AgeAccel (GrimAge) was moderately correlated with BMI, $\rho = 0.52$ ($p = 0.01$). This association could be spurious and needs testing in larger samples in future work, as after applying Bonferroni correction for multiple testing, the association was not significant.

### Discussion

In this study, we examined the epigenetic age of uterine myometrium sampled from term pregnant individuals undergoing cesarean birth in comparison to maternal chronological age and to epigenetic age of matched maternal blood samples using the Horvath pan-tissue clock, the GrimAge clock, the Hannum clock, and the PhenoAge clock. The primary findings were that (1) three of the four clocks measured epigenetic age within the two tissues and (2) epigenetic age was significantly positively correlated between blood and myometrium in the same three clocks. However, AgeAccel was only correlated using the GrimAge calculator. To our knowledge, this is the first study to report using epigenetic age to assess myometrium and matched blood epigenetic age.

In our study, while epigenetic age was correlated with chronological age each clock’s median biological age significant differed from maternal chronological age (Grim/Hannum younger and pan-tissue Horvath older). This discrepancy between clocks may be a feature of how the clocks were originally generated and validated. Epigenetic age, as described by Horvath et al. [21], was developed as a tool for estimating biological age and derived from elastic net regression that identified a set of CpG sites that are correlated with age among 82 different cell and tissue types (including cervix, endometrium but not myometrium). Therefore, the original Horvath clock is used to examine epigenetic age in multiple tissue types. The original Horvath Clock was followed by several other epigenetic “clocks” which were validated against other useful measures of physiologic function and consist of sets of CpG sites for each clock, with little overlap. Further description of the epigenetic clocks is available.

Pregnancy represents a unique state of change in the body, and may lead to unique changes in DNA methylation patterns (especially in the myometrium and reproductive tissues), therefore, current epigenetic age estimates may not be as useful because they were
validated in non-pregnant populations. This may explain why we had different biological age estimates from the different clocks used in our study. This finding also creates an opportunity for future validation of a pregnancy-specific maternal epigenetic clock that examines aging across the pregnancy and reflects biological age related to pregnancy-specific outcomes. Alternatively, cellular aging of different organs/tissues may occur at different time points over the life course, as found in mouse models of aging [29]. Furthermore, researchers using Horvath’s clock have shown that human breast tissue epigenetic age seems to be older than age derived from blood DNA, similar to our findings comparing myometrium/blood [30]. However, this difference could be related to less precise age estimates for hormone responsive tissue like breast/endometrium using the CpGs included in the original Horvath clock [21]. Work is ongoing to improve the breast-tissue specific CpG patterns estimating epigenetic age [31].

The study of biological aging using an epigenetic clock is a relatively new approach yet has not been robustly applied to studying/predicting poor maternal health outcomes. One study of endometrial (uterine lining) aging also found that epigenetic age in the endometrium was relatively older than chronological age [32], similar to our finding using Horvath’s clock in myometrium. While endometrium and myometrium share some similarities including embryonic origin (mesenchyme) and steroid hormone-responsiveness, the myometrial layer develops distinct features of smooth muscle through induction by the epithelial layer (future endometrium) [33, 34]. Uterine endometrium proceeds to proliferate and degenerate

---

**Table 2** Spearman Rho correlations between tissues for epigenetic age and age acceleration

| Correlation                  | Epigenetic clock | \( \rho \) | \( p \) value |
|------------------------------|------------------|-----------|---------------|
| Blood and myometrial         | Horvath          | 0.60      | 0.004         |
| epigenetic age               | Hannum           | 0.62      | 0.003         |
|                              | GrimAge          | 0.81      | < 0.001       |
| Blood and myometrial         | Horvath          | 0.28      | 0.21          |
| epigenetic age acceleration  | Hannum           | 0.20      | 0.37          |
|                              | GrimAge          | 0.49      | 0.02          |

**Fig. 1** Blood and myometrial DNA methylation using three epigenetic clocks. The distribution of epigenetic age for each clock (labeled on right hand side of graph) by tissue is presented with the distribution of chronological age of the sample for reference.
with cyclic changes in ovarian hormones. The stroma retains clonogenic properties of mesenchymal stem cells [35, 36]. Cyclic modulation of endometrium may be controlled in part by epigenetic mechanisms [37]. With aging, the function of endometrium is affected by the loss of stem cells [38] as well as by decreased proliferation necessary for establishing implantation, driven by lower estrogen production.

In contrast, research on myometrium in healthy reproductive aged humans is more limited. While myometrium does not undergo significant changes with the ovarian cycle, there is evidence of stem cell involvement in tissue function for remodeling during pregnancy and possibly for coordinating myometrial contractions during labor [39, 40]. In addition, myocytes respond to rising steroid hormones during pregnancy with progesterone repressing gene expression for contraction-associated proteins during early pregnancy. As estriol rises, myocytes increase gene transcription for contraction-associated proteins (oxytocin receptors, prostaglandin receptors, and gap junctions) [4, 41]. Some prior studies did not find differences in contractile ability in myometrial tissue specimen by maternal age [11, 15]; however, others have noted lower responsiveness to oxytocin stimulation [42] or lower electromyographic activity [43]. Clinical studies report that older parturients have longer labors [44] and more often need oxytocin in labor [8], and higher dosages of oxytocin are needed for third-stage labor to prevent uterine atony [45]. The specific reasons for the differences observed by studies of vitro contractility studies and clinical outcomes by age prompts further study.

Other studies of epigenetic aging involving pregnancy have largely focused on newborn or child epigenetic clock measures or outcomes. For example, maternal depression (as well as SSRI use) has been associated with epigenetic age differences in newborn DNA [46–49]. Researchers might consider if maternal aging is associated with mental illness or other measures of social stress during pregnancy as has been noted in non-pregnant samples [50, 51]. Relevant to preterm birth, GrimAge AgeAccel assessed prenatally predicted shorter gestational age and lower birthweight in the newborn [27]. Epigenetic age has been applied to the study of health disparities by race/ethnic subgroups [52, 53]. Given that disparities in
maternal mortality and morbidity by racial groups widens with advancing age [18, 54], examining epigenetic age would also be useful for those interested in examining biological age in association with experiences of stress, discrimination, economic, or social disadvantage [55, 56]. Given the rising age for first and subsequent pregnancies (as well as age-related disease like cardiovascular disease and diabetes), the concept of biological aging and epigenetic age specifically may be a useful measure for future research on maternal morbidity or development of age-related disorders in pregnancy.

Furthermore, given our finding of higher GrimAge AgeAccel in myometrial tissue with higher body mass index, future work should consider both age and body composition on uterine aging and outcomes. While maternal age is closely linked to more labor dysfunction, a growing scientific literature also links higher body mass to poor outcomes as well [7, 57]. Maternal adiposity has been linked to alterations in placental DNA methylation and gene transcription; however, epigenetic clock methods were not applied to the methylation data in this study [58]. Whether BMI plays a role in accelerated aging, which mediates the relationship between age and myometrial function, should be investigated further.

Research implications
Myometrial function has been studied in relationship to the aging reproductive population. This study contributes to the body of work examining how age-related biological differences may be important to myometrial function during pregnancy. From a broad perspective, further work on epigenetic age may highlight important variability in outcomes across the maternal age spectrum. If consistent with other literature on epigenetic aging, this tool could be an informative indicator of “Advanced Maternal Age” in terms of biological age as advancements in epigenetic assays occur (i.e., improved speed, lower cost). However, before that is possible, the significance of these epigenetic age differences (AgeAccel) needs to be determined in future studies of physiologic function and clinical outcomes. For example, will Horvath’s clock or GrimAge be a more useful predictor of healthy physiologic labor and birth or severe maternal morbidity? Our study helps support the premise that blood is a useful proxy for myometrial epigenetic age, given future studies of outcomes of vaginal birth will need to rely upon the blood derived DNA for epigenetic age assessment. Samples obtained earlier in pregnancy might be useful in studying birth-related outcomes linked to myometrial function (i.e., prolonged pregnancy, prolonged labor etc.) but may also be informative at predicting other pregnancy-related conditions like preeclampsia. Furthermore, epigenetic age might also be a compelling biomarker for determining if interventions designed to improve the health of pregnant women (diet/exercise, stress reduction, aspirin therapy) are detected in the biological age of the individual.

Strengths and limitations
Despite a more limited sample size than anticipated, significant correlations in epigenetic age were consistently found between myometrium and blood. Data availability and having a small sample size limited our ability to assess potential confounders that may influence age acceleration. This study would have been strengthened by in vitro studies of myometrial contraction in relationship to aging but was not possible given the preservation methods of the tissue. Furthermore, none of the participants underwent labor; thus, we cannot conclude that these samples represent a wider sample of the population due to the nature of having planned cesarean birth. Limited clinical data and sample size prohibited more stratification by specific obstetric or medical conditions.

Conclusions
Using existing epigenetic clock methods, epigenetic age in maternal blood is correlated with maternal myometrium at delivery, and GrimAge AgeAccel correlated between tissues as well. Future studies should evaluate the clinical relevance of AgeAccel in predicting age-associated complications during pregnancy and parturition.

Materials and methods
Aim
The first aim of this study was to determine if existing epigenetic age measures (clocks) relate to maternal age in both the uterine myometrium and maternal blood (i.e., validity of the measures). Second, we sought to assess the association between epigenetic age measured in maternal blood and myometrium for potential future use of blood epigenetic age as a biomarker of myometrial epigenetic age.

Design
This study was a comparative study examining epigenetic age, as calculated using different epigenetic clocks, in both maternal blood and myometrium.

Participants
Data used in this study were available via a pregnancy-related tissue repository managed by (blinded institution). Potential participants engaged in a consent process with trained research staff to participate, which included donating samples of myometrium, whole maternal blood, placenta, and cord blood. Participants whose samples were used in this study also specifically provided
and preprocessed using R statistical suite (version 3.6.1). Data for over 850,000 CpGs was generated per sample amplified, hybridized, and imaged. DNA methylation was converted using an EZ DNA Methylation Kit (Zymo), Five hundred nanograms of each sample was bisulfite converted using an EZ DNA Methylation Kit (Illumina, San Diego, USA).

Tissue samples were obtained from pregnant individuals undergoing planned cesarean birth at 37 weeks or greater [59]. Indications for delivery varied, including elective primary or repeat cesarean; several participants had chronic or gestational hypertension or proteinuria though none of the cesarean births were performed urgently due to a medical indication. A small portion of full-thickness myometrium (measuring approximately 2 cm × 2 cm in size) was excised bluntly from the edge of the hysterotomy incision shortly after delivery of the newborn. The surgical staff handed the myometrial specimen to study staff shortly after birth, the myometrium was rinsed briefly in phosphate-buffered saline, dissected from serosa and any endometrium, if present, and flash frozen in liquid nitrogen in small sections. Whole blood was also frozen in aliquots after being collected in standard EDTA tubes in the 1-2 h prior to delivery via venipuncture. Whole blood was frozen and stored at −80 °C until DNA was isolated. Specimens were collected from a total of 27 participants; however, only 25 had both tissue samples collected.

**Procedures**

**DNA extraction and methylation**

The DNA was isolated from whole blood specimens and myometrium using QIAmp DNA Mini Kits. DNA was then quantitated by fluorescence using Quant-iT™ PicoGreen® dsDNA assay kit (Invitrogen | Thermo Fisher Scientific).

DNA methylation was then assessed using Illumina's MethylationEPIC BeadChip (Illumina, San Diego, USA). Five hundred nanograms of each sample was bisulfite converted using an EZ DNA Methylation Kit (Zymo), amplified, hybridized, and imaged. DNA methylation data for over 850,000 CpGs was generated per sample and preprocessed using R statistical suite (version 3.6.1). IDAT files from the Illumina array were loaded into the R package, Minfi. Noob background correction was performed, and detection p-value and beta value sample files were generated for over 850,000 CpGs. During quality control, 5 samples with low signal, and 2532 CpG sites with high missingness were excluded. Previously identified cross-reactive probes were dropped [60]. After quality control, 819,723 CpG sites and 21 matched myometrial and blood samples remained.

**Epigenetic clock calculator**

After completing quality control, epigenetic age was calculated separately for blood and myometrial samples using Horvath’s website (https://dnage.genetics.ucla.edu). Specifically, using the online calculator, we examined pan-tissue Horvath [21], Hannum [22], PhenoAge [23], and GrimAge [24] clocks for this study.

**Statistical analyses**

Epigenetic age data for both myometrium and blood resulting from the four different clock calculators were examined with histograms for dispersion within the tissues. Spearman correlation was used to first compare each epigenetic age to maternal (chronological) age given the distribution. Clocks that correlated significantly with maternal age at rho ≥ 0.5 in both tissues were considered in the subsequent analyses (this included the pan-tissue Horvath, GrimAge, and Hannum clocks). We then examined the Spearman correlation between the tissues types for the valid clocks. Tests of differences in epigenetic age to chronological age by tissue were conducted using paired t-tests/Wilcoxon signed-rank tests as appropriate for each clock. For each clock, we calculated the epigenetic age acceleration (AgeAccel) from the residual of a linear regression of DNA methylation age (epigenetic age produced by the given clock) on chronological age creating the following variables: pan-tissue Horvath AgeAccel, GrimAge AgeAccel, and Hannum AgeAccel. For each clock, we then calculated Spearman correlations for AgeAccel between tissues. Finally, we tested the correlation of maternal pre-pregnancy BMI with each clock’s estimated epigenetic age and AgeAccel across the sample as a post hoc examination given the limited clinical data available for these specimens (with Bonferroni correction). The rationale for this additional analysis was based on knowledge that higher maternal BMI has been linked to uterine dysfunction during labor [7] and that researchers have reported associations of higher BMI with greater AgeAccel (using pan-tissue Horvath clock) in both liver and adipose tissue samples [61, 62]. Statistical significance was set at p < 0.05.
Acknowledgements
The authors wish to acknowledge and thank the Placenta Repository Principal Investigator (Dr. Leonardo Pereira), project staff who gathered specimens at delivery, and team lead (Dr. Monica Rincond) and Dr. Natasha Singh and Professor Mark Johnson (Imperial College, University of London, and obstetricians at (Oregon Health and Science University and Chelsea and Westminster Hospital) for their contribution to the sample collection for this study. We are also grateful to the participants in this study and acknowledge their sample donation.

Authors’ contributions
EE conceptualized, designed, and managed the study including tissue acquisition, in addition to analyzing and interpreting the data. AK performed the epigenetic clock calculations and was a major contributor in writing the manuscript. AS contributed to the data analysis and interpretation of findings. All authors read and approved the final manuscript.

Funding
Funding support listed below had no role in the study design or presentation of the findings. Dr. Erickson is supported by the NIH, National Institute for Nursing Research under award number 1K99NR019596-01. This study was also supported by the Building Interdisciplinary Research Careers in Women’s Health (BIRCWH) K12 Program funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development of the NIH under award numbers K12HD043488 (Dr. Erickson) and K12HD085850 (Dr. Knight) and grants by the Oregon Clinical Translational Research Institute Participant and Clinical Interactions Management Award under award number CTRC ULTR002369. Additional support was provided by ULTR002378 by the Georgia Clinical Translational Science Alliance.

Availability of data and materials
Data used in this study may be available through repository request submitted to the guardian of the tissue repository at (blinded institution).

Declarations
Ethics approval and consent to participate
Ethics board approval was sought for the tissue repository which provided the specimens, and a request for determination was received for use of the de-identified tissues.

Consent for publication
n/a

Competing interests
The authors declare that they have no competing interests.

Author details
1Midwifery Division, School of Nursing, Oregon Health and Science University, 3455 SW US Veterans Hospital Rd, Portland, OR 97239, USA.
2Gynecology & Obstetrics; Emory University, 100 Woodruff Circle, Atlanta, GA 30322, USA.
3Obstetrics & Gynecology, School of Medicine, Oregon Health and Science University, 3030 S. Moody Avenue, Suite 110, Portland, OR 97201, USA.

Received: 13 December 2021 Accepted: 4 May 2022
Published: 23 May 2022

References
1. Rydahl E, Declercq E, Juhl M, Maimburg RD. Cesarean section on a rise—does advanced maternal age explain the increase? A population register-based study. PLoS ONE. 2019;14(1):e0210655.
2. Waldenstrom U, Ekéus C. Risk of labor dystocia increases with maternal age irrespective of parity: a population-based register study. Acta Obstet Gynecol Scand. 2017;96(9):1063–9.
3. Wen T, Overton EE, Sheen JJ, Attenello FJ, Mack-Wi, D’Alton ME, et al. Risk for postpartum readmissions and associated complications based on maternal age. J Matern Fetal Neonatal Med. 2019;34(9):1375–81.
4. Mitsuya K, Singh N, Sooranna SR, Johnson MR, Myatt L. Epigenetics of human myometrium: DNA methylation of genes encoding contraction-associated proteins in term and preterm labor. Biol Reprod. 2014;90(5):590–8.
5. Helguezera G, Eghbali M, Sforza D, Minosyan TY, Tolo R, Stefani E. Changes in global gene expression in rat myometrium in transition from late pregnancy to parturition. Physiol Genomics. 2009;36(2):89–97.
6. Helguera G, Eghbali M, Sforza D, Minosyan T, Tolo R, Stefani E. Changes in global gene expression in rat myometrium in the transition from late pregnancy to parturition. Physiol Genomics. 2008; Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19001510.
7. Carlson NS, Hernandez TL, Hurt KJ. Parturition dysfunction in obesity: time to target the pathobiology. Reprod Biol Endocrinol. 2015;13(1):1–14.
8. Main DM, Main MK, Moore DH. The relationship between maternal age and uterine dysfunction: a continuous effect throughout reproductive life. Am J Obstet Gynecol. 2000;182(6):1312–20.
9. Aryama K, Pinto R, Ray JG, Hill AD, Scales DC, Lapinsky SE, et al. Association of maternal age with severe maternal morbidity and mortality in Canada. JAMA Netw Open. 2019;2(8):e199875.
10. Atkins A, Mulla ZD, Plivics SK. Outcomes of women delivering at very advanced maternal age. J Womens Health. 2018;27(11):1378–84.
11. Crankshaw DJ, O’Brien YM, Crosby DA, Morrison JJ. Maternal age and contractility of human myometrium in pregnancy. Reprod Sci. 2015;22(10):1299–35.
12. Pirhonen J, Bergersen TK, Abdlenoor M, Dubiel M, Gudmundsson S. Effect of maternal age on uterine flow impedance. J Clin Ultrasound JCU. 2005;33(1):14–7.
13. Sweeney EM, Dockery P, Crankshaw DJ, O’Brien YM, Walsh JM, Morrison JJ. Human uterine lower segment myometrial cell and nuclear volume at term: influence of maternal age. J Anat. 2014;225(6):625–33.
14. Du Q, Jovanović S, Tulic L, Šljivančanin DS, Jack DW, ŽiŽić V, et al. KATP channel genes are up-regulated with increasing age in human myometrium. Mech Ageing Dev. 2013;134(4):98–102.
15. Arrowsmith S, Robinson H, Noble K, Wray S. What do we know about what happens to myometrial function as women age? J Muscle Res Cell Motil. 2012;33(3–4):209–17.
16. Patel R, Moffatt JD, Mourmoura E, Demaison L, Seed PT, Poston L, et al. Effect of reproductive ageing on pregnant mouse uterus and cervix. J Physiol. 2017;595(6):2065–84.
17. Elmes M, Szyszka A, Paulant C, Clifford B, Daniel Z, Cheng Z, et al. Maternal age effects on myometrial expression of contractile proteins, uterine gene expression, and contractile activity during labor in the rat. Physiol Rep. 2015;3(4):e12305.
18. Schummers L, Hutcheon JA, Hacker MR, Vanderweelee TJ, Williams PL, McElrath TF, et al. Absolute risks of obstetric outcomes risks by maternal age at first birth: A population-based cohort. Epidemiology. 2018;29(3):379–87.
19. Ryan CP. “Epigenetic clocks”: theory and applications in human biology. Am J Hum Biol. 2020;32(4):e23488.
20. Oblik L, van der Zgan A, Higgins-Chen AT, Levine ME, Boks MP. A systematic review of biological, social and environmental factors associated with epigenetic clock acceleration. Ageing Res Rev. 2021;69:101348.
21. Horvath S. DNA methylation age of human tissues and cell types. Genome Biol. 2013;14(10):R115.
22. Hannum G, Guinne J, Zhao L, Zhang L, Hughes G, Sidda SV, et al. Genome-wide methylation profiles reveal quantitative views of human aging rates. Mol Cell. 2013;49(2):359–67.
23. Levine ME, Lu AT, Quach A, Chen BH, Assimes TL, Bandinelli S, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging. 2018;10(4):573–91.
24. Lu AT, Quach A, Wilson JG, Reiner AP, Aviv A, Raj K, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging. 2019;11(2):303–27.
25. Horvath S, Raj K. DNA methylation-based biomarkers and the epigenetic clock theory of ageing. Nat Rev Genet. 2018;19(6):371–84.

26. Ross KM, Carroll J, Horvath S, Hobel CJ, Coussons-Read ME, Dunkel SC. Immune epigenetic age in pregnancy and 1 year after birth: associations with weight change. Am J Reprod Immunol 1989;20:83(S):e13229.

27. Ross KM, Carroll JE, Horvath S, Hobel CJ, Coussons-Read ME, Dunkel SC. Epigenetic age and pregnancy outcomes: GravAge acceleration is associated with shorter gestational length and lower birthweight. Clin Epigenetics. 2020;12(1). Available from: https://pubmed.ncbi.nlm.nih.gov/32762768/.

28. Correlation and regression | The BMJ. The BMJ | The BMJ: leading general medical journal. Research. Education. Comment. 2020 [cited 2022 Apr 20]. Available from: https://www.bmj.com/about-bmj/resources-read/publications/statistics-square-one/11-correlation-and-regression.

29. Schauf N, Lehaller B, Hahn O, Pálovics R, Hosseinizadeh S, Lee SE, et al. Aging hallmarks exhibit organ-specific temporal signatures. Nature. 2020;583(7817):596–602.

30. Sehl ME, Henry JE, Storniolo AM, Ganz PA, Horvath S. DNA methylation age is elevated in breast tissue of healthy women. Breast Cancer Res Treat. 2017;164(1):209–19.

31. Castle JR, Lin N, Liu J, Storniolo AMV, Shendre A, Hou L, et al. Estimating breast tissue-specific DNA methylation age using next-generation sequencing data. Clin Epigenetics. 2020;12(1):45.

32. Olesen MS, Starnawksa A, Bybjerg-Graulhum J, Bieffeld AP, Agerholm L, Forman A, et al. Biological age of the endometrium during pregnancy using DNA methyla- tion. Reproduction. 2018;155(2):167–72.

33. Cunha GR, Assimes TL, Ferrucci L, Horvath S, Levine ME. The role of epigenetic aging in education and racial/ethnic mortality disparities among older U.S. Women. Psychoneuroendocrinology. 2019;104:18–24.

34. Cunha GR, Baskin L. Mesenchymal-epithelial interaction techniques. Differentiation. 2016;91(4):20–7.

35. Cunha GR, Young P, Brody JR. Role of uterine epithelium in the develop- ment of myometrial smooth muscle cells. Biol Reprod. 1989;40(4):861–71.

36. Gargett CE, Schwab KE, Deane JA. Endometrial stem/progenitor cells: the first 10 years. Hum Reprod Update. 2016;22(2):137–63.

37. Retis-Resendiz AM, González-García IN, León-Juéz M, Carnacho-Arroyo I, Cérbon M, Vázquez-Martínez ER. The role of epigenetic mechanisms in the regulation of gene expression in the cyclical endometrium. Clin Epigenetics. 2021;13(1):116.

38. Lucas Es, Dyer NP, Fishwick K, Ott S, Baskin LJ, Sowers B, et al. Identification of polymorphic and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip. Genomics Data. 2020;9:22–4.

39. Kaga K, Ono M, Iizuka T, Matsumoto T, Hosono T, Sekizuka-Kagami N, et al. Novel third mesh-like myometrial layer connects the longitudinal and circular muscle fibers: a potential stratum to coordinate uterine contractions. Sci Rep. 2020;10(1):8274.

40. Ono M, Moriyama I, Starken J, Chaligne F, Rafferty A, Mckenna P, et al. Identification of polymorphic and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip. Genomics Data. 2020;9:22–4.

41. Horvath S, Erhart W, Brossch M, Ammerpohl O, von Schönfels W, Ahrens M, et al. Obesity accelerates epigenetic aging of human liver. Proc Natl Acad Sci U S A. 2014;111(43):15338–43.

42. de Toro-Martín J, Guénard F, Tchernof A, Hould FS, Lebel S, Julien F, et al. Body mass index is associated with epigenetic age acceleration in the visceral adipose tissue of subjects with severe obesity. Clin Epigenetics. 2019;11(1):172.

43. Shrestha D, Workalemahu T, Tekola-Ayelle F. Maternal dyslipidemia during early gestation and epigenetic ageing of the placenta. Epigenetics. 2019;14(10):1030–9.

44. Girschken P, Lahti J, Czamara D, Knight AK, Jones MJ, Suarez A, et al. Associations between maternal risk factors of adverse pregnancy and birth outcomes and the offspring epigenetic clock of gestational age at birth. Clin Epigenetics. 2017;9(1):49.

45. Suarez A, Lahti J, Czamara D, Lahti-Pulkkinen M, Knight AK, Girschken P, et al. The epigenetic clock at birth: associations with maternal antenatal depression and child psychiatric problems. J Am Acad Child Adolesc Psychiatry. 2018;57(5):321–328.e2. Available from: www.jaacap.org.

46. Marečková K, Pačinková A, Klasna J, Shin J, Andréjsová K, Stano-Kozubík K, et al. Epigenetic clock as a correlate of anxiety. Neurolmage Clin. 2020;28:102458.

47. Wolf EJ, Logue MW, Morrison FG, Wilcox ES, Stone A, Schichman SA, et al. Posttraumatic psychopathology and the pace of the epigenetic clock: a longitudinal investigation. Psychol Med. 2019;49(5):791–800.

48. Lucas ES, Dyer NP, Fishwick K, Ott S, Brosens JJ. Success after failure: the role of endometrial stem cells in recurrent miscarriage. Reproduction. 2020;167(1):83–93.

49. Castle JR, Lin N, Liu J, Storniolo AMV, Shendre A, Hou A, et al. Estimating breast tissue-specific DNA methylation age using next-generation sequencing data. Clin Epigenetics. 2020;12(1):45.

50. Lucas Es, Dyer NP, Fishwick K, Ott S, Baskin LJ, Sowers B, et al. Identification of polymorphic and off-target probe binding sites on the Illumina Infinium MethylationEPIC BeadChip. Genomics Data. 2020;9:22–4.

51. Mckenna BG, Hendrix CL, Brennan PA, Smith AK, StoweZN, Newport DJ, et al. Maternal prenatal depression and epigenetic age deceleration: testing potentially confounding effects of prenatal stress and SSRI use; 2020. Available from: https://doi.org/10.1080/15592294.2020.1795604.